This post was originally published on this site
Merck joins a growing list of drugmakers, including Pfizer Inc (NYSE:PFE), Eli Lilly (NYSE:LLY), Novartis and Abbvie Inc, which are pausing investments or scaling back their business in Russia after Moscow’s invasion of Ukraine.
Western companies have come under pressure to leave Russia, but the healthcare sector has not pulled out because medicines and medical devices and equipment are considered necessary for humanitarian reasons and are excluded from sanctions.
Merck said it would deliver 135,000 courses of its COVID-19 pill, molnupiravir, to Ukraine under a supply agreement with the government.
The company does not have any research or production facilities in Russia, a company spokesperson said.
